Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpiNet-First Trial 1 for new-onset focal epilepsy
ACTRN12615000643572Phase 4Terminated
- Sponsor
- EpiNet Study Group
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 4, randomised, open-label trial in epilepsy and Focal Onset Epilepsy comparing Levetiracetam monotherapy, Lamotrigine monotherapy and Carbamazepine monotherapy (3 arms). Primary endpoint: Time to 12-month remission from seizures. Started Jul 2015; status: terminated.
02
Drugs
levetiracetamlamotriginecarbamazepine
03
Conditions
epilepsyFocal Onset Epilepsy
Beyond the preview
Go deeper on ACTRN12615000643572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000643572.